Thalidomide before and after autologous stem cell transplantation in recently diagnosed multiple myeloma (HOVON-50): long-term results from the phase 3, randomised controlled trial

Niels W. C. J. van de Donk, Bronno van der Holt, Monique C. Minnema, Edo Vellenga, Sandra Croockewit, Marie Jose Kersten, Peter A. von dem Borne, Paula Ypma, Ron Schaafsma, Okke de Weerdt, Saskia K. Klein, Michel Delforge, Mark-David Levin, Gerard M. Bos, Kon-Siong G. Jie, Harm Sinnige, Jules L. L. M. Coenen, Esther G. de Waal, Sonja Zweegman, Pieter SonneveldHenk M. Lokhorst

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)E479-E492
Number of pages14
JournalThe Lancet Haematology
Volume5
Issue number10
DOIs
Publication statusPublished - 1 Oct 2018

Keywords

  • PROGRESSION-FREE SURVIVAL
  • LOW-DOSE DEXAMETHASONE
  • CONSOLIDATION THERAPY
  • MAINTENANCE THERAPY
  • INDUCTION TREATMENT
  • PLUS DEXAMETHASONE
  • RESPONSE CRITERIA
  • 2ND MALIGNANCIES
  • TARGETING CD38
  • OPEN-LABEL

Cite this